Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
3.4
Journals
Current Oncology
Special Issues
Combined Therapies for Hepatocellular Carcinoma
share announcement

Combined Therapies for Hepatocellular Carcinoma

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 20 July 2026 | Viewed by 8112

Special Issue Editor

Dr. Hooman Yarmohammadi

E-Mail Website
Guest Editor
Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
Interests: hepatocellular carcinoma; cholangiocarcinoma; pancreas cancer; radioembolization; antiglycolytic therapy; tumor embolization; tumor ablation; vascular-targeted phototherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, necessitating innovative treatment strategies to improve patient outcomes. This Special Issue of Current Oncology explores the evolving role of combination therapies in HCC management, highlighting the latest advancements in multimodal treatment approaches. The aim of this Special Issue is to provide a comprehensive overview of these innovative treatment paradigms, offering insights into emerging clinical data, patient selection criteria, and future directions in the management of patients with HCC. We invite researchers to address one of these topics related to the synergistic potential of radioembolization and immunotherapy, the benefits of chemoembolization combined with surgery, the value of integrating immunotherapy with targeted therapy, the role of external beam radiation in combination with systemic therapy or other locoregional treatments, and/or the potential benefits of combined locoregional therapies, such as transarterial chemoembolization (TACE) and ablation, in optimizing local tumor control and prolonging survival in patients with HCC.

This Special Issue, entitled “Combined Therapies for Hepatocellular Carcinoma”, welcomes the submission of studies that address any combination of surgery, interventional radiology, external beam radiation and systemic options, and the immunotherapy of targeted therapies.

In this Special Issue, original research articles and reviews are welcome. The scope of this Special Issue includes, but is not limited to, the following topics:

  1. Radioembolization plus immunotherapy in treating patients with HCC.
  2. Chemoembolization as an adjuvant to surgical resection in treating patients with HCC.
  3. Combined immunotherapies/targeted therapies for the treatment of patients with HCC.
  4. External beam radiation combined with systemic options in treating patients with HCC.
  5. Combined locoregional therapies for treating patients with HCC.

I look forward to receiving your contributions.

Dr. Hooman Yarmohammadi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • combined therapies
  • immunotherapy
  • locoregional therapy
  • external beam radiation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 363 KB  
Article
Safety of Combination TARE and SBRT in Hepatocellular Carcinoma: A Review of Literature & Single-Center Case Series
by Bahareh Gholami, Ali Afrasiabi, Andrew M. Moon, Ted K. Yanagihara, Hui Wang, Sandra Gad, Alex Villalobos, David M. Mauro, Hyeon Yu, Johannes L. du Pisanie and Nima Kokabi
Curr. Oncol. 2025, 32(9), 487; https://doi.org/10.3390/curroncol32090487 - 31 Aug 2025
Cited by 1 | Viewed by 1333
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. At the time of diagnosis, many HCC patients are not candidates for surgical resection and are considered for other locoregional therapies, including transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT). To date [...] Read more.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. At the time of diagnosis, many HCC patients are not candidates for surgical resection and are considered for other locoregional therapies, including transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT). To date only a few studies have explored the safety and efficacy of combining TARE and SBRT. Therefore, we aimed to evaluate it. Patients who received both SBRT and TARE from 2016 to 2024 were retrospectively evaluated for treatment-related toxicity based on criteria for adverse events (CTCAE v4.0). Treatment response was evaluated by modified response evaluation criteria for solid tumors (m-RECIST). We identified 12 patients with median age of 66.5 (range: 40, 87) and median follow up of 12 months. The median time between TARE and SBRT was 6.5 months (range: 1.5 to 24). Following the second treatment, ALBI grade remined the same among all patients at 3-month post treatment compared to baseline. Baseline CP was A among all patients and remained unchanged during follow-up and no higher than grade 3 clinical or biochemical toxicity was seen. The objective response rate (ORR) among patients receiving treatment to the same lesion was 100%. The combination treatment was consistent with prior studies in which the combination of TARE and SBRT has been shown to have good local control with few cases of grade 3 toxicity. Our study demonstrates that treatment with TARE and SBRT was safe and effective among our small sample of patients. Full article
(This article belongs to the Special Issue Combined Therapies for Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 324 KB  
Review
Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects
by Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Motoyuki Kohjima and Masatake Tanaka
Curr. Oncol. 2025, 32(9), 490; https://doi.org/10.3390/curroncol32090490 - 31 Aug 2025
Cited by 1 | Viewed by 2588
Abstract
The focus of treatment of hepatocellular carcinoma (HCC) has shifted significantly from local therapy to systemic drug therapy. Recently, the efficacy of drug therapy for HCC has made rapid progress. We have transitioned from eras of sorafenib monotherapy and sequential therapy with multiple [...] Read more.
The focus of treatment of hepatocellular carcinoma (HCC) has shifted significantly from local therapy to systemic drug therapy. Recently, the efficacy of drug therapy for HCC has made rapid progress. We have transitioned from eras of sorafenib monotherapy and sequential therapy with multiple tyrosine kinase inhibitors that slightly improved patient prognoses, to an era where the introduction of immunotherapy combining atezolizumab and bevacizumab has achieved further improvements in patient prognosis. The availability of highly effective drugs has expanded the range of diseases treatable by drug therapy. Additionally, instead of initiating drug therapy at advanced stages, combining it with local therapies such as transarterial chemoembolization at an earlier stage with the aim of achieving a cure has become possible, improving treatment outcomes further. Currently, the number of regimens available for HCC, including combinations of multiple drugs and local therapies, has increased, leading to numerous clinical trials. Additionally, HCC cases that were previously unresectable are now resectable after drug therapy, necessitating the establishment of a resectability classification system. This review summarizes the current evidence for drug therapy for HCC and discusses future treatment strategies, treatment combinations, and prospects. Full article
(This article belongs to the Special Issue Combined Therapies for Hepatocellular Carcinoma)
16 pages, 1316 KB  
Review
Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements
by Wei Xu, Qing Li and Bin Liang
Curr. Oncol. 2025, 32(6), 313; https://doi.org/10.3390/curroncol32060313 - 28 May 2025
Cited by 1 | Viewed by 3738
Abstract
Intermediate- and advanced-stage hepatocellular carcinoma (HCC) continues to present significant therapeutic challenges. Hepatic artery infusion chemotherapy (HAIC), a well-established locoregional treatment for unresectable HCC, has recently demonstrated promising clinical outcomes both as monotherapy and in combination with systemic therapies. This comprehensive review examines [...] Read more.
Intermediate- and advanced-stage hepatocellular carcinoma (HCC) continues to present significant therapeutic challenges. Hepatic artery infusion chemotherapy (HAIC), a well-established locoregional treatment for unresectable HCC, has recently demonstrated promising clinical outcomes both as monotherapy and in combination with systemic therapies. This comprehensive review examines recent clinical advances in HAIC for HCC, with particular emphasis on evolving treatment regimens and their therapeutic efficacy. Full article
(This article belongs to the Special Issue Combined Therapies for Hepatocellular Carcinoma)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop